Get the latest on MindMed’s Q3 2025 earnings: clinical trial milestones, financial strength, and pivotal Phase III data readouts expected in 2026.

CLEVELAND, Ohio — Browns head coach Kevin Stefanski took questions from reporters on Wednesday with regard to coming off the bye week, preparing for the New York Jets, Tommy Rees calling plays, and ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

When a business engages in any economic activity, such as selling goods, purchasing supplies or paying salaries, these events must be recorded in the financial books. This is the first phase of the ...

Tonix prepares for the November 2025 launch of Tonmya with 3Q25 revenue growth, strong cash, higher SG&A, and a robust ...

Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today ...

Commercial Center Expansion -- 14 cancer centers now approved to purchase RenovoCath, up from five at the start of 2025; five ...

With its European and Chinese partners, Kiwi drug minnow AFT Pharmaceuticals plans a 1000-patient trial of a novel iron ...

Sonder’s Chapter 7 bankruptcy and abrupt shutdown are creating disruption for landlords nationwide and raising new questions ...

Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026Advancements in ...

REVOLUTION, Invivyd’s development program for VYD2311, comprises the DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID ...